Statements (81)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
other pharmaceutical companies
Daiichi Sankyo's anti-influenza drug business Sankyo's anti-infective business |
| gptkbp:aims_to |
improve patient outcomes
|
| gptkbp:collaborated_with |
non-profit organizations
academic institutions philanthropic organizations |
| gptkbp:collaborates_with |
research institutions
|
| gptkbp:conducts |
clinical trials
|
| gptkbp:dedicated_to |
advancing HIV science
|
| gptkbp:depicted_in |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:develops |
antiretroviral drugs
combination therapies for HIV diagnostic tools for HIV long-acting HIV therapies therapeutics for co-infections with HIV |
| gptkbp:employees |
approximately 5,000
|
| gptkbp:employs |
scientists and researchers
|
| gptkbp:established |
partnerships with governments
collaborative research projects. research partnerships with universities clinical guidelines for HIV treatment |
| gptkbp:focuses_on |
patient-centered care
HIV treatment reducing stigma around HIV treatment adherence strategies |
| gptkbp:founded |
1878
|
| gptkbp:founder |
gptkb:Taikichiro_Shionogi
|
| gptkbp:global_presence |
in multiple countries
|
| gptkbp:has_achievements |
milestones in HIV drug development
|
| gptkbp:has_product |
HIV medications
|
| gptkbp:headquartered_in |
gptkb:Osaka,_Japan
|
| gptkbp:headquarters |
gptkb:Osaka,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shionogi
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:invention |
HIV treatment formulations
|
| gptkbp:investment |
HIV research
biotechnology for HIV |
| gptkbp:is_active_in |
clinical research networks
patient education initiatives |
| gptkbp:is_committed_to |
sustainable practices
|
| gptkbp:is_engaged_in |
community outreach programs
healthcare policy discussions public health advocacy |
| gptkbp:is_involved_in |
global health initiatives
HIV vaccine research HIV prevention efforts HIV treatment guidelines development |
| gptkbp:is_known_for |
innovative therapies
its patient support initiatives its research pipeline |
| gptkbp:is_part_of |
global pharmaceutical industry
|
| gptkbp:is_recognized_for |
its contributions to HIV research
its commitment to innovation |
| gptkbp:offers |
educational resources for healthcare professionals
support programs for patients |
| gptkbp:participated_in |
international conferences on HIV
HIV drug approval processes HIV-related workshops |
| gptkbp:participates_in |
HIV awareness campaigns
|
| gptkbp:partnership |
healthcare providers
|
| gptkbp:partnerships |
various global pharmaceutical companies
|
| gptkbp:produced_by |
generic HIV medications
|
| gptkbp:products |
antibiotics
antiviral drugs pain management medications |
| gptkbp:provides |
patient assistance programs
|
| gptkbp:received |
regulatory approvals for HIV drugs
|
| gptkbp:research_areas |
various locations
|
| gptkbp:research_focus |
central nervous system disorders
infectious diseases pain management |
| gptkbp:revenue |
$1.5 billion (2020)
|
| gptkbp:stock_exchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:subsidiary |
gptkb:Shionogi_Inc.
gptkb:Shionogi_Pharma,_LLC |
| gptkbp:symbol |
4507
|
| gptkbp:website |
www.shionogi.com
|
| gptkbp:bfsParent |
gptkb:baloxavir_marboxil
|
| gptkbp:bfsLayer |
5
|